Related references
Note: Only part of the references are listed.Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
Matthew J. Streetly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
